1. Biochemistry and Chemical Biology
  2. Structural Biology and Molecular Biophysics

Dynamics of allosteric regulation of the phospholipase C-γ isozymes upon recruitment to membranes

  1. Edhriz Siraliev-Perez
  2. Jordan TB Stariha
  3. Reece M Hoffmann
  4. Brenda RS Temple
  5. Qisheng Zhang
  6. Nicole Hajicek
  7. Meredith L Jenkins
  8. John E Burke  Is a corresponding author
  9. John Sondek  Is a corresponding author
  1. Department of Biochemistry and Biophysics, School of Medicine, University of North Carolina at Chapel Hill, United States
  2. Department of Biochemistry and Microbiology, University of Victoria, Canada
  3. Division of Chemical Biology and Medicinal Chemistry, School of Pharmacy, University of North Carolina at Chapel Hill, United States
  4. Lineberger Comprehensive Cancer Center, School of Pharmacy, University of North Carolina at Chapel Hill, United States
  5. Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, United States
  6. Department of Biochemistry and Molecular Biology, The University of British Columbia, Canada
https://doi.org/10.7554/eLife.77809
Share this article
Cite this article
  1. Edhriz Siraliev-Perez
  2. Jordan TB Stariha
  3. Reece M Hoffmann
  4. Brenda RS Temple
  5. Qisheng Zhang
  6. Nicole Hajicek
  7. Meredith L Jenkins
  8. John E Burke
  9. John Sondek
(2022)
Dynamics of allosteric regulation of the phospholipase C-γ isozymes upon recruitment to membranes
eLife 11:e77809.
https://doi.org/10.7554/eLife.77809
  2. Download BibTeX
  3. Download .RIS

Abstract

Numerous receptor tyrosine kinases and immune receptors activate phospholipase C-γ (PLC-γ) isozymes at membranes to control diverse cellular processes including phagocytosis, migration, proliferation, and differentiation. The molecular details of this process are not well understood. Using hydrogen-deuterium exchange mass spectrometry, we show that PLC-γ1 is relatively inert to lipid vesicles that contain its substrate, phosphatidylinositol 4,5-bisphosphate (PIP2), unless first bound to the kinase domain of the fibroblast growth factor receptor (FGFR1). Exchange occurs throughout PLC-γ1 and is exaggerated in PLC-γ1 containing an oncogenic substitution (D1165H) that allosterically activates the lipase. These data support a model whereby initial complex formation shifts the conformational equilibrium of PLC-γ1 to favor activation. This receptor-induced priming of PLC-γ1 also explains the capacity of a kinase-inactive fragment of FGFR1 to modestly enhance the lipase activity of PLC-γ1 operating on lipid vesicles but not a soluble analog of PIP2 and highlights potential cooperativity between receptor engagement and membrane proximity. Priming is expected to be greatly enhanced for receptors embedded in membranes and nearly universal for the myriad of receptors and co-receptors that bind the PLC-γ isozymes.

Editor's evaluation

This work provides insight into how phospholipase C-γ1 (PLC-γ1) becomes activated upon binding to phosphorylated receptor tyrosine kinase, with an analysis of PLC-γ1 bound to the soluble kinase domain of FGFR1 (FGFR1K) and/or liposomes containing PIP2. The most interesting finding is that regions of the protein far from the FGFR1K binding site increase in exchange upon binding. This is new information for a large protein that is arguably difficult to study, but it conforms to what has been observed in many other autoinhibited systems with similar SH2 and SH3 domains such as kinases. The results will be of interest to structural biologists and cell biologists with interest in the mechanisms leading to the regulation of phospholipase C activity on membranes.

https://doi.org/10.7554/eLife.77809.sa0

Introduction

The 13 mammalian phospholipase C (PLC) isozymes hydrolyze the minor membrane phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2) to create the second messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) (Gresset et al., 2012; Kadamur and Ross, 2013). IP3 diffuses throughout the cytosol and binds to IP3-gated receptors in the endoplasmic reticulum, resulting in an increase in the concentration of intracellular calcium ions. In contrast, DAG remains embedded in the inner leaflet of the plasma membrane, where it recruits and activates multiple signaling proteins containing C1 domains including the conventional isoforms of protein kinase C (PKC). In addition, DAG is a precursor of phosphatidic acid, itself an important signaling lipid. PLC-dependent depletion of PIP2 levels in the plasma membrane also regulates the activity of numerous ion channels and signaling proteins. Accordingly, the PLCs orchestrate fluctuations in the abundance of both phospholipids and second messengers to control important biological processes including proliferation (Noh et al., 1995) and cell migration (Asokan et al., 2014).

The PLC-γ isozymes, PLC-γ1 and PLC-γ2, are activated downstream of myriad cell surface receptors and regulate signaling cascades that modulate multiple aspects of embryonic development, directed cell migration, and the immune response. Mounting evidence also indicates that the PLC-γ isozymes are drivers of human disease including cancer and immune disorders (Koss et al., 2014). For example, PLC-γ1 is overexpressed and presumably activated in breast cancer (Arteaga et al., 1991). In addition, genome-wide sequencing studies have identified somatic gain-of-function mutations in PLC-γ1 and PLC-γ2 in a variety of immunoproliferative malignancies. In one cohort of patients with adult T-cell leukemia/lymphoma, PLC-γ1 is the most frequently mutated gene with almost 40% of patients harboring at least one substitution in the isozyme (Kataoka et al., 2015). Moreover, mutations in PLC-γ2 arise in approximately 30% of patients with relapsed chronic lymphocytic leukemia after treatment with ibrutinib, a covalent inhibitor of Bruton’s tyrosine kinase (Woyach et al., 2014). Recently, a putative gain-of-function variant was identified in PLC-γ2, Pro522Arg, that was associated with a decreased risk of late-onset Alzheimer’s disease (Sims et al., 2017). This variant also seems to slow cognitive decline in patients with mild cognitive impairment (Kleineidam et al., 2020), suggesting that in some contexts, elevated PLC-γ activity is beneficial.

Among the PLCs, PLC-γ1 and PLC-γ2 are distinct in that they are the only isozymes directly activated by tyrosine phosphorylation. It is widely accepted that phosphorylation of Tyr783 in PLC-γ1 and the equivalent site in PLC-γ2, Tyr759, is required for their regulated activation (Kim et al., 1991; Kim et al., 1990; Watanabe et al., 2001). Phosphorylation and consequently, activation of the PLC-γ isozymes are mediated by two major classes of tyrosine kinases. Multiple receptor tyrosine kinases (RTKs) including receptors for growth factors such as fibroblast growth factor (Burgess et al., 1990), as well as Trk receptors (Vetter et al., 1991) activate the PLC-γ isozymes. PLC-γ1 and PLC-γ2 are also phosphorylated by soluble tyrosine kinases associated with immune receptors, including members of the Src, Syk, and Tec families (Law et al., 1996; Nakanishi et al., 1993; Schaeffer et al., 1999).

PLC-γ1 and PLC-γ2 contain a distinctive array of regulatory domains that controls their phosphorylation-dependent activation. The phosphorylation sites required for lipase activity (Tyr783 in PLC-γ1 and Tyr759 in PLC-γ2) are located within this array (Gresset et al., 2010; Kim et al., 1991; Nishibe et al., 1990). The array also harbors two SH2 domains, nSH2 and cSH2, which mediate binding of tyrosine kinases (Nishibe et al., 1990) and autoinhibition of lipase activity (Gresset et al., 2010), respectively. Indeed, deletion or mutation of the cSH2 domain is sufficient to constitutively activate PLC-γ1 in vitro and in cells (Gresset et al., 2010; Hajicek et al., 2013). Importantly, the release of autoinhibition mediated by the cSH2 domain is coupled directly to the phosphorylation of Tyr783 (Gresset et al., 2010). A PLC-γ1 peptide encompassing phosphorylated Tyr783 (pTyr783) binds to the isolated cSH2 domain with high affinity (KD ~360 nM). In the context of the full-length isozyme, mutation of the cSH2 domain such that it cannot engage phosphorylated tyrosines ablates kinase-dependent activation of PLC-γ1 in vitro. Presumably, the intramolecular interaction between pTyr783 and the cSH2 domain drives a substantial conformational rearrangement resulting in activation of the enzyme. In addition to these regulatory components, the array also harbors scaffolding properties mediated by a split pleckstrin homology (sPH) domain and an SH3 domain that bind multiple signaling and adaptor proteins including the monomeric GTPase Rac2 (Walliser et al., 2008) and SLP-76 (Yablonski et al., 2001), respectively.

The X-ray crystal structure of essentially full-length PLC-γ1 highlights how the regulatory array integrates these myriad functions (Hajicek et al., 2019) (Figure 1A–B). In the autoinhibited state, the array is positioned directly on top of the catalytic core of the enzyme. This arrangement, coupled with the overall electronegative character of the array effectively blocks the lipase active site from spuriously engaging the plasma membrane. Two major interfaces anchor the regulatory array to the catalytic core. The first interface is formed between the cSH2 domain and the C2 domain, and essentially buries the surface of the cSH2 domain that engages the region encompassing pTyr783. The second interface is comprised of the sPH domain and the catalytic TIM barrel. More specifically, the sPH domain sits atop the hydrophobic ridge in the TIM barrel, effectively capping the ridge and preventing its insertion into membranes, a requisite step in the interfacial activation of PLC isozymes. In contrast, the phosphotyrosine-binding pocket on the nSH2 domain, as well as the polyproline-binding surface on the SH3 domain are solvent exposed, implying that these elements are pre-positioned to efficiently engage activated RTKs and adaptor proteins, respectively. The overall architecture of the regulatory array is consistent with an enzyme that is unable to access membrane-resident substrate in the basal state. Upon activation of an RTK, e.g., FGFR1, the nSH2 domain mediates recruitment of PLC-γ1 to the phosphorylated tail of the receptor, and PLC-γ1 is subsequently phosphorylated by FGFR1 on Tyr783. pTyr783 then binds to the cSH2 domain, unlatching it from the catalytic core. This binding event is likely coupled to additional structural rearrangements of the regulatory array with respect to the catalytic core that ultimately allows the active site to access PIP2 embedded in membranes (Hajicek et al., 2019; Liu et al., 2020).

Figure 1 with 1 supplement see all
Download asset Open asset
Domain architecture of phospholipase C-γ1 (PLC-γ1) and initial hydrogen-deuterium exchange mass spectrometry time course.

(A) Domain schematic of PLC-γ1. Full-length PLC-γ1 possesses a set of regulatory domains inserted within its catalytic core. (B) Structure of PLC-γ1. In the basally autoinhibited state shown here (PDB ID: 6PBC), the regulatory domains prevent access to membranes by the catalytic core demarked by a Ca2+ cofactor (orange). His335 is also within the catalytic core and its substitution (H335A) renders the isozyme catalytically inactive (yellow). Asp1165 substitution (D1165H) disrupts the interface between the core and the regulatory array leading to a constitutively active lipase (also yellow). (C) Relative levels of deuterium incorporation are colored on the structure of PLC-γ1 (residue 21–1215) according to the legend at either 3 or 10,000 s of D2O exposure.

Figure 1—source data 1

Raw mass spectral data of deuterium incorporation per peptide.

https://cdn.elifesciences.org/articles/77809/elife-77809-fig1-data1-v1.xlsx
Figure 1—source data 2

Unprocessed images.

Raw images of gels used to produce final figures.

https://cdn.elifesciences.org/articles/77809/elife-77809-fig1-data2-v1.zip

Although the core aspects of autoinhibition and phosphorylation-dependent regulation are relatively well established, less is known about the chronology of events subsequent to receptor binding that result in lipase activation. A comparison of the structure of autoinhibited PLC-γ1 and a structure of the tandem SH2 domains of PLC-γ1 bound to the phosphorylated kinase domain of FGFR1 (Bae et al., 2009) suggests a cogent sequence of events. In autoinhibited PLC-γ1, kinase engagement by the nSH2 domain would partially expose the surface of the cSH2 domain that binds pTyr783. Binding of pTyr783 would then fully displace the cSH2 domain from the catalytic core, presumably initiating and propagating the larger structural rearrangements that disrupt the remainder of the autoinhibitory interface, culminating in membrane engagement. Cooperativity between nSH2 and cSH2 domains of PLC-γ1 has been described previously (Bunney et al., 2012); however, the functional consequences of this cooperativity were linked to a reduction in the affinity for FGFR1 with no corresponding effect on lipase activity.

Here, we use hydrogen-deuterium exchange mass spectrometry (HDX-MS) to define changes in PLC-γ1 dynamics upon engagement of PIP2-containing liposomes and the phosphorylated kinase domain of FGFR1. PLC-γ1 was largely quiescent in the presence of liposomes. In contrast, rapid and widespread changes in exchange kinetics were observed in a PLC-γ1-FGFR1 complex. These changes were centered on the nSH2 domain and also encompassed large swaths of the autoinhibitory interface. Changes in this exchange profile were further amplified in PLC-γ1 bound to both FGFR1 and liposome. These results are consistent with in vitro lipase assays demonstrating that engagement of FGFR1 was sufficient to elevate PLC-γ1 activity, and suggest a model in which receptors and membranes act together to prime the lipase for full activation.

Results

Widespread changes in the hydrogen-deuterium exchange of PLC-γ1 by kinase and liposomes

In order to assess the dynamics of PLC-γ1 using HDX-MS, it was first necessary to establish optimized conditions for protein coverage, a suitable time course of H/D exchange and constructs suitable for membrane binding. These parameters were addressed in two steps. First, optimization of HDX-MS conditions allowed for the generation of 254 peptides covering ~92% of the PLC-γ1 sequence, with an average peptide length of 13 amino acids. H/D exchange was carried out at five time points (3, 30, 300, 3000, and 10,000 s), which allowed for the interrogation of differences in both highly dynamic and stable regions of secondary structure (Figure 1C). Second, it was necessary to design and ensure a system that would allow PLC-γ1 to interact with PIP2-containing liposomes over the time course of the exchange reaction without the catalytic conversion of the liposomes. This outcome was accomplished by introduction of a single substitution (H335A) into PLC-γ1 of a catalytic residue necessary for PIP2 hydrolysis (Figure 1B). Although several substitutions of active site residues are known to render PLCs catalytically inactive (Ellis et al., 1998), His335 was specifically chosen for its role in the enzymatic process. More specifically, based on analogy to PLC-δ1, His335 is predicted to coordinate the incoming water molecule required for PIP2 hydrolysis; it is predicted to be required during the transition state but should have little effect on the affinity of PLC-γ1 for PIP2 as a substrate. In addition, His335 does not ligate the calcium ion cofactor in the crystal structure of PLC-γ1 and for this reason is unlikely to perturb the overall structure of the active site.

Consequently, PLC-γ1 (H335A) was purified and its lack of catalytic activity verified using a fluorescent substrate embedded within liposomes (Figure 1—figure supplement 1). In addition, a flotation assay was used to show that PLC-γ1 (H335A) retains capacity to associate with PIP2-containing liposomes (Figure 1—figure supplement 1). For flotation measurements, proteins were initially treated to chelate calcium and free calcium concentrations were maintained below 400 nM to prevent substantial PIP2 hydrolysis by WT PLC-γ1.

Once we determined PLCγ-1 was amenable to studies by HDX-MS, changes in the hydrogen-deuterium exchange profile of PLC-γ1 (H335A) were measured in response to either: (i) PIP2-containing lipid vesicles (90% PE/10% PIP2), (ii) the kinase domain of FGFR1 (FGFR1K) phosphorylated at Tyr766, or (iii) both vesicles and phosphorylated kinase (Figure 2). Tyrosine 766 is a major site of phosphorylation in FGFR1 and phosphorylated Tyr766 directly binds PLC-γ1 to recruit it to membranes in cells (Eswarakumar et al., 2005; Mohammadi et al., 1991). Phosphorylated Tyr766 of FGFR1K is also the major site of interaction between the kinase domain and the tandem SH2 array of PLC-γ1 in a crystal structure of these fragments in complex (Bae et al., 2009). Consequently, the kinase domain of FGFR1 was mutated to remove minor sites of tyrosine phosphorylation and to render the kinase resistant to phosphorylation-dependent activation before phosphorylation of Tyr766 and formation of a stable complex with PLC-γ1 (H335A) (Figure 2—figure supplement 1, Figure 2—figure supplement 2).

Figure 2 with 4 supplements see all
Download asset Open asset
Widespread changes in deuterium exchange of phospholipase C-γ1 (PLC-γ1) upon binding kinase domain of fibroblast growth factor receptor (FGFR1K).

Significant differences in deuterium incorporation are mapped on the structure of PLC-γ1 (H335A) according to the legend for the following three states: alone versus bound to phosphorylated kinase domain of fibroblast growth factor receptor (FGFR1K) (A), alone versus in the presence of liposomes containing phosphatidylethanolamine:phosphatidylinositol 4,5-bisphosphate (90:10) (B), or alone versus bound to both pFGFR1K and liposomes (C). In addition, Figure 2—figure supplement 4 shows differences in exchange of PLC-γ1 (H335A) bound to either liposomes or pFGFR1K relative to a final state with PLC-γ1 (H335A) bound to both liposomes and pFGFR1K. Significant differences in any peptide required three specific conditions: greater than both a 5% and 0.4 Da difference in exchange at any time point (3, 30, 300, 3000, and 10,000 s), and a two-tailed, unpaired t-test of p<0.01. The #D difference for each condition is graphed below, which shows the total difference in deuterium incorporation over the entire hydrogen-deuterium exchange time course, with each point indicating a single peptide (error shown as SD [n=3]). Each circle represents the central residue of a corresponding peptide with the full deuterium exchange information for all peptides available in the source data. Individual peptides with a significant difference as defined above are colored red.

FGFR1K potentially disrupts autoinhibition

There were widespread, significant differences in H/D exchange that occurred in PLC-γ1 (H335A) upon binding phosphorylated FGFR1K (Figure 2A). For all reported significant changes in H/D exchange, three specific conditions had to be met: greater than both a 5% and 0.4 Da difference in exchange at any time point, and a two-tailed, unpaired t-test of p<0.01. The full HDX data, and differences are reported in the source data.

Only the nSH2 domain of PLC-γ1 showed significantly decreased exchange upon binding FGFR1K. It is this domain that directly engages phosphorylated Tyr766 in the crystal structure of the kinase domain of FGFR1 bound to the tandem SH2 domains of PLC-γ1 (Figure 2—figure supplement 3; Bae et al., 2009). Consequently, the most straightforward interpretation of the reduced exchange in the complex is that it reflects the major sites of interaction between phosphorylated FGFR1 and PLC-γ1. In fact, regions of reduced exchange within the nSH2 domain match exceptionally well to those regions that directly interact with the phosphorylated portion of FGFR1K in the crystal structure. These regions of the nSH2 domain include the N-terminal portion of the αA helix and the C-terminal portion of the βB strand that interact directly with phosphorylated Tyr766 as well as the βE/βF and αB/βG loops that interact with regions of FGFR1K proximal to phosphorylated Tyr766 (Figure 2A, Figure 2—figure supplement 3, Figure 2—figure supplement 4). These data are consistent with previously reported differences in H/D exchange in PLC-γ1 upon binding FGFR1K (Liu et al., 2020).

In contrast to decrease exchange localized to the nSH2 domain, exchange was significantly increased throughout much of PLC-γ1 (H335A) upon binding FGFR1K (Figure 2A, Figure 2—figure supplement 4). In particular, increased exchange was widespread throughout the interface between the regulatory array and the catalytic core required for autoinhibition of lipase activity. For example, on one side of the interface, all of the loops within the TIM barrel that comprise the hydrophobic ridge showed increased exchange. This increased exchange was mirrored on the other side of the interface by widespread increases in exchange of most of the split PH domain. In fact, the entire first half of the sPH domain along with the first strand (β4) of the second half of the sPH domain showed increased exchange. Indeed, some of the largest increases in percent exchange were found within the β4 strand and the immediately preceding loop that interacts with the hydrophobic ridge of the TIM barrel in the autoinhibited form of PLC-γ1. Loops of the C2 domain interacting with the cSH2 domain form another important part of the autoinhibitory interface and two of these loops (β3/β4, β5/β6) within the C2 domain also showed heightened hydrogen-deuterium exchange. More peripheral regions of exchange include portions of the first two EF hands that directly support the β3/β4 loop of the C2 domain.

As described earlier, FGFR1K principally interacts with the nSH2 domain of PLC-γ1 (Bae et al., 2009; Chattopadhyay et al., 1999; Ji et al., 1999) such that many of the sites of increased exchange within PLC-γ1 are distant from the main binding site of FGFR1K. Consequently, while it is undoubtedly the case that the binding of FGFR1K to PLC-γ1 leads to widespread increases in the hydrogen-deuterium exchange kinetics of PLC-γ1, it is not readily apparent how FGFR1K promotes this increased exchange. Nonetheless, the increased exchange throughout the autoinhibitory interface is indicative of its increased mobility, suggesting that kinase engagement is sufficient to loosen the autoinhibitory interface and prime PLC-γ1 for more complete activation upon its phosphorylation by the kinase. This idea has been suggested previously (Hajicek et al., 2019).

In contrast to the widespread changes in the exchange profile of PLC-γ1 (H335A) upon engagement of phosphorylated FGFR1K, PIP2-containing liposomes incubated with PLC-γ1 (H335A) produced more limited differences that were mostly restricted to the periphery of the lipase (Figure 2B, Figure 2—figure supplement 4). Overall, there were no regions of significantly decreased exchange and only three, discrete, non-contiguous regions of significantly increased exchange. Two of the regions of increased exchange were restricted to relatively small portions of either the SH3 domain (β2) or the TIM barrel (β6/α5/α5’). A larger region of exchange manifested within the two SH2 domains and encompasses regions of the nSH2 domain (αA/βB) near the site of interaction with phosphorylated Tyr766 of FGFR1K, the linker between the two SH2 domains, and the terminal portion of the cSH2 domain (αB/βG) required for autoinhibition through interactions with the C2 domain. This third, larger region is compelling since it suggests a propensity of the nSH2 domain to interact with membranes and place it within proximity of phosphorylated receptors such as FGFR1 in order to facilitate the docking of PLC-γ1 with active transmembrane receptors. It also suggests that membranes impact regions between the two SH2 domains as well as within the cSH2 domain to possibly facilitate release of autoinhibition. Nonetheless, the overall magnitudes of differences in exchange in response to liposomes are small compared to the differences observed upon FGFR1K engagement (Figure 2A–B, Figure 2—figure supplement 4). This result suggests multiple points of transient engagement of PLC-γ1 with liposomes or cellular membranes in the absence of transmembrane binding partners. This scenario is also consistent with the tight, basal autoinhibition of PLC-γ1 in cells in the absence of a relevant, activated transmembrane receptor (Gresset et al., 2010). However, in the presence of relevant activated receptors as represented by phosphorylated FGFR1, the interaction of membranes with PLC-γ1 may help PLC-γ1 to engage receptors and may subsequently cooperate with receptors to facilitate release of lipase autoinhibition.

Cooperation between FGFR1 and membranes in the regulation of PLC-γ1 is also consistent with the hydrogen-deuterium exchange pattern of PLC-γ1 observed in the presence of both FGFR1K and liposomes (Figure 2C, Figure 2—figure supplement 4). Overall, similar patterns of differences in exchange are observed for the same regions of PLC-γ1 affected by either component alone. Indeed, the overlap of the exchange profiles is rather striking and is a testament to the reproducibility of the experimental technique. However, when both FGFR1K and liposomes were present, there were enhanced increases in exchange in PLC-γ1 compared to either condition alone. These increases manifest primarily within the SH3 domain and the catalytic TIM barrel. Overall, HDX-MS data suggest a modest, synergistic cooperation between FGFR1K and liposomes to increase the conformational flexibility of the regulatory domains relative to the catalytic core of PLC-γ1.

Oncogenic substitution of PLC-γ1 mimics engagement by kinase and liposomes

The PLC-γ1 interface between its regulatory domains and catalytic core is frequently mutated in certain cancers and immune disorders (Koss et al., 2014). We have previously proposed that these mutations likely disrupt this interface leading to elevated, basal phospholipase activity (Hajicek et al., 2019). If true, oncogenic substitutions at this interface in PLC-γ1 might recapitulate changes in deuterium exchange in PLC-γ1 observed upon binding phosphorylated FGFR1K. This idea was tested using HDX-MS and PLC-γ1 (H335A) harboring an additional substitution (D1165H) frequently found in leukemias and lymphomas (Kataoka et al., 2015) (Figure 3). To make sure that there were no complications from the use of the H335A mutant, we also carried out HDX-MS experiments comparing D1165 versus D1165H in a catalytically active background (H335), which showed very similar differences in exchange upon mutation of D1165 (Figure 1—source data 1).

Figure 3
Download asset Open asset
Oncogenic substitution of phospholipase C-γ1 (PLC-γ1) mimics kinase engagement.

(A) Significant differences in deuterium incorporation for PLC-γ1 (H335A) versus the oncogenic mutant of PLC-γ1 (H335A+D1165H) were determined and mapped on the structure of PLC-γ1. (B) The #D difference upon mutation shows the total difference in deuterium incorporation over the entire hydrogen-deuterium exchange time course, with each point indicating a single peptide (error shown as SD [n=3]). Individual peptides with a significant difference between conditions (defined as greater than both a 5% and 0.4 Da difference in exchange at any time point, and a two-tailed, unpaired t-test of p<0.01) are colored red. (C) A selection of peptides showing significant differential exchange at any time point (data shown as mean ± SD [n=3]), asterisks indicate significant time points for peptides as defined above. Full deuterium exchange data is available in the source data.

Asp1165 resides in a loop between strands β5 and β6 of the C2 domain where it is required to stabilize extensive interactions between the C2 and cSH2 domains. These interactions are required to maintain PLC-γ1 in an autoinhibited state since the basal activity of PLC-γ1 (D1165H) is ~1500-fold higher than the WT phospholipase (Hajicek et al., 2019).

In comparison to catalytically inactive PLC-γ1 harboring H335A, the same version of PLC-γ1 with the addition of D1165H exhibited increased deuterium exchange throughout the interface between the regulatory domains and the catalytic core (Figure 3). In the immediate vicinity of D1165H, deuterium exchange increased within the β6 strand of the C2 domain suggesting that Asp1165 serves to support the position of the β6 strand. This idea is consistent with previous molecular dynamics simulations of PLC-γ1 that highlighted an unraveling of the β6 strand upon introduction of D1165H (Hajicek et al., 2019). The previous molecular dynamics simulations also highlighted a relatively large (~10 Å) movement of the cSH2 upon collapse of the β6 strand, and this movement may be reflected in the increased exchange of the nearby αB helix and αB/βG loop of the cSH2 domain. Other regions of increased exchange are more distant and include portions of the first EF hand, sPH domain, and TIM barrel. Overall, regions of increased exchange in catalytically inactive PLC-γ1 (D1165H) overlap well with regions of increased exchange in PLC-γ1 (H335A) when it engages phosphorylated FGFR1K (Figure 2A). This comparison further supports the notion that disengagement of the catalytic core from the regulatory domains will enhance lipase activity, with oncogenic mutations and binding to phosphorylated FGFR1K mediating this process. Indeed, it should be noted that regions of increased exchange are more extensive in the complex of PLC-γ1 and FGFR1K suggesting that oncogenic mutations cannot fully recapitulate activation by phosphorylated FGFR1K.

Oncogenic substitution uncovers functional cooperativity within PLC-γ1

Constitutively active variants of PLC-γ1 and PLC-γ2 have untapped reserves of lipase activity. For example, although PLC-γ1 (D1165H) possesses exceptionally high basal lipase activity, this activity can be further enhanced in cells by the epidermal growth factor receptor suggesting that normal cellular regulation is partially preserved in constitutively active forms of PLC-γ1 (Hajicek et al., 2019). To test this idea, changes in the hydrogen-deuterium exchange profile of PLC-γ1 (H335A+D1165H) were determined in response to phosphorylated FGFR1K, liposomes, or both (Figure 4, Figure 4—figure supplement 1, Figure 4—figure supplement 2). In comparison to the identical measurements described earlier using PLC-γ1 (H335A), these measurements are particularly revealing for several reasons.

Figure 4 with 2 supplements see all
Download asset Open asset
Oncogenic substitution uncovers functional cooperativity within phospholipase C-γ1 (PLC-γ1).

Differences in deuterium incorporation were measured for PLC-γ1 (H335A+D1165H) in three states: alone versus bound to phosphorylated kinase domain of fibroblast growth factor receptor (pFGFR1K) (A), alone versus in the presence of phosphatidylethanolamine:phosphatidylinositol 4,5-bisphosphate (90:10) liposomes (B), or alone versus with both pFGFR1K and liposomes present (C). In addition, Figure 4—figure supplement 1 shows differences in exchange of PLC-γ1 (H335A+D1165H) bound to either liposomes or pFGFR1K relative to a final state with PLC-γ1 (H335A+D1165H) bound to both liposomes and pFGFR1K. Differences in deuterium exchange for a series of time points (3, 30, 300, 3000, and 10,000 s) were calculated relative to PLC-γ1 (H335A+D1165H) alone and peptides with significant differential exchange at any time point (both a 5% and 0.4 Da difference in exchange at any time point, and a two-tailed, unpaired t-test of p<0.01) mapped onto the structure. The #D difference for each condition is graphed below, which shows the total difference in deuterium incorporation over the entire hydrogen-deuterium exchange time course, with each point indicating a single peptide (error shown as SD [n=3]); peptides with significant differences between conditions as defined above are red.

First, phosphorylated FGFR1K produced almost identical changes in the exchange profiles of the two forms of PLC-γ1 as highlighted in the comparison of Figures 2A and 4A (see also Figure 4—figure supplement 1). Not only does this result further attest to the reproducibility of the experimental design, it also strongly suggests that WT and constitutively active forms of PLC-γ1 respond similarly to engagement by kinases.

Second, and in contrast to effects mediated by phosphorylated FGFR1K, PIP2-containing liposomes produced much more extensive and widespread changes in the hydrogen-deuterium exchange profile of mutant PLC-γ1 (H335A+D1165H) (Figure 4B, Figure 4—figure supplement 1) compared to PLC-γ1 (H335A) (Figure 2B). For example, while no portion of the EF hands of PLC-γ1 (H335A) showed differences in exchange upon addition of liposomes, the entire first EF hand (Eα1/Fα1) as well as the start of the second EF hand (Eα2) of PLC-γ1 (H335A+D1165H) showed increased exchange. In addition, the adjacent β3/β4 loop of the C2 domain had robustly increased exchange upon membrane binding in the D1165H variant, whereas this region in PLC-γ1 (H335A) was essentially unresponsive to lipids. In the same vein, while liposomes elicited only relatively modest and discrete increases in the exchange of the regulatory domains of PLC-γ1 (H335A), under the same conditions, there were widespread and robust increases in exchange within the regulatory domains of PLC-γ1 (H335A+D1165H). These regions include the entire first half of the sPH domain, the majority of both the nSH2 and SH3 domains, as well as the EF and BG loops (βE/βF, αB/βG) of the cSH2 domain critical for autoinhibition of lipase activity.

Third, and perhaps most intriguing, while liposomes failed to decrease exchange of any part of PLC-γ1 (H335A), under identical conditions, several portions of PLC-γ1 (H335A+D1165H) exhibited decreased exchange. These regions of decreased exchange are primarily in the TIM barrel: β2-β2’ and β7 strands as well as the subsequent loops comprising the majority of the hydrophobic ridge. The hydrophobic ridge is generally assumed to insert into membranes during interfacial catalysis and the decreased exchange of this region may indicate its direct interaction with liposomes during aborted attempts at catalysis. A second region of decreased exchange encompasses α1 of the sPH domain as well as the adjoining linker connecting to the second half of the TIM barrel. This linker is disorderd in the crystal structure of full-length PLC-γ1 and it is intriguing to speculate that this region may act as a hinge that allows the regulatory array to move in order to allow access of liposomes to the hydrophobic ridge.

Finally, the exchange profile of PLC-γ1 (H335A+D1165H) upon the addition of both phosphorylated FGFR1K and liposomes (Figure 4C) approximately resembles the composite profile of each component alone, with two interesting caveats. First, a portion of the linker between the cSH2 and SH3 domains that includes frequently phosphorylated Tyr771 possesses decreased exchange that cannot be accounted by a composite profile. This difference presumably reflects structural changes in PLC-γ1 (H335A+D1165H) that arise due to cooperative interactions among the PLC isozyme, FGFR1K, and liposomes. This presumption is reinforced by the second caveat: in the presences of both FGFR1K and liposomes, there is a striking synergy in the differences in exchange for PLC-γ1 (H335A+D1165H) compared to PLC-γ1 (H335A), with liposomes enhancing the changes observed with only FGFR1K approximately two-fold (Figure 4C, lower panel). These regions include most of the first and second EF hands as well as a large segment of the second half of the TIM barrel spanning strands β6 and β7 and including helices α5 and α5’.

Overall, the exchange results indicate that the oncogenic substitution, D1165H, leads to a much more conformationally flexible PLC-γ1 that more readily interacts with lipid bilayers, possibly in a fashion that mirrors interfacial catalysis by PLC isozymes. This process would require a large movement by the regulatory domains as suggested by the icons in Figure 4.

Phosphorylated FGFR1K increases PLC-γ1 specific activity

The HDX kinetics described above strongly suggest that the initial engagement of PLC-γ isozymes by kinases may be sufficient to enhance phospholipase activity irrespective of subsequent phosphorylation. This idea was tested using XY-69 (Huang et al., 2018), a fluorescent analog of PIP2, embedded in lipid vesicles (Figure 5). PLCs readily hydrolyze XY-69 leading to increased fluorescence that can be followed in real time. As shown previously, when XY-69 in lipid vesicles is mixed with PLC-γ1, the specific activity of the phospholipase is low, indicative of basal autoinhibition. This activity remained unchanged upon pre-incubation of PLC-γ1 with catalytically inactive FGFR1K that was not phosphorylated. In contrast, when PLC-γ1 was pre-incubated with catalytically inactive FGFR1K phosphorylated at Tyr766 to promote complex formation with PLC-γ1, the specific lipase activity of PLC-γ1 increased approximately three-fold. These results indicate that kinase engagement by PLC-γ1 is sufficient to enhance lipase activity and supports the proposition that PLC-γ1 is allosterically modulated by FGFR1K upon complex formation and irrespective of the phosphorylation state of the lipase.

Figure 5
Download asset Open asset
Phosphorylated kinase domain of fibroblast growth factor receptor (FGFR1K) increases phospholipase C-γ1 (PLC-γ1) specific activity.

(A) Specific activities measured with the membrane-embedded substrate XY-69. XY-69 (0.5 μM) was incorporated into liposomes comprised of phosphatidylethanolamine:phosphatidylinositol 4,5-bisphosphate (80:20) prior to addition of indicated variants of PLC-γ1 (10 nM WT; 0.3 nM D1165H). Specific activities were calculated for PLC-γ1 alone and in the presence of either unphosphorylated FGFR1K or its phosphorylated counterpart (pFGFR1K). (B) Specific activities of PLC-γ1 (D1165H) measured with water-soluble WH-15 (5 μM). In all cases, specific activities are presented as the mean ± SD of three independent experiments (n=3), each with three or more technical replicates. Statistical significance was determined with a two-tailed, unpaired t-test.

Similar results were observed with PLC-γ1 (D1165H). In particular, addition of catalytically inactive, phosphorylated FGFR1K increased the basal lipase activity of PLC-γ1 (D1165H) approximately two-fold. The basal capacity of PLC-γ1 (D1165H) to hydrolyze vesicle-embedded XY-69 was substantially higher than the equivalent activity of WT PLC-γ1, but this result has been previously published (Huang et al., 2018) and comports with the higher constitutive activity of PLC-γ1 (D1165H) in cells (Patel et al., 2020). Interestingly, the addition of catalytically inactive but non-phosphorylated FGFR1K also led to a significant increase in the specific activity of PLC-γ1 (D1165H). We are unable to readily account for this observation, but it should be noted that the crystal structure of phosphorylated FGFR1K bound to the two SH2 domains of PLC-γ1 highlights a secondary interface outside of the canonical pTyr-binding site that contributes to the affinity of the complex (Bae et al., 2009). Therefore, unphosphorylated FGFR1K may have sufficient affinity for PLC-γ1 that it is able to enhance the lipase activity of constitutively active PLC-γ1 (D1165H) but not the more basally autoinhibited, WT form.

Autoinhibition of the PLC-γ isozymes presumably arises due to steric hindrance by the regulatory array preventing the catalytic core from productively engaging lipid membranes to hydrolyze XY-69. In contrast, WH-15 is a soluble, fluorescent substrate of PLCs that is insensitive to the autoregulation of the PLC-γ isozymes (Huang et al., 2011). As expected, the hydrolysis of WH-15 by PLC-γ1 (D1165H) is insensitive to either form of FGFR1K (Figure 5B), and these results further support the idea that the complex of FGFR1K and PLC-γ1 diminishes autoregulation by loosening the conformational ensemble of the autoinhibited form of PLC-γ1.

Discussion

A general model for the regulated activation of the PLC-γ isozymes posits a conserved, catalytic core that is basally prevented from accessing its lipid substrate, PIP2, when PIP2 is embedded in membranes (Figure 6). In essence, the two-dimensional nature of the membrane bilayer is key to this regulation since soluble substrates such as PIP2 in detergent bypass this regulation and freely access the solvent-accessible active site. In contrast, the active site of PLC-γ isozymes is prevented from accessing PIP2 in membranes by a set of regulatory domains that must undergo conformational rearrangements before the catalytic core can dock with membranes and engage PIP2. This model derives from substantial cellular (DeBell et al., 2007; DeBell et al., 1999; Horstman et al., 1999; Poulin et al., 2000; Schade et al., 2016), biochemical (Bunney et al., 2012; Gresset et al., 2010; Poulin et al., 2005), and biophysical (Bunney et al., 2012; Hajicek et al., 2013) data and is perhaps most self-evident for the high-resolution structure of autoinhibited, full-length PLC-γ1 that highlights the arrangement of the regulatory domains relative to the catalytic core that prevents productive engagement of membranes (Hajicek et al., 2019).

Figure 6
Download asset Open asset
Multi-step activation of phospholipase C-γ1 (PLC-γ1).

Initially, fibroblast growth factor receptor (FGFR1) is monomeric and inactive while PLC-γ1 is cytosolic and basally autoinhibited (A). Growth factor-promoted dimerization of FGFR1 leads to its tyrosine phosphorylation and the recruitment of PLC-γ1 through interactions mediated by the nSH2 domain of PLC-γ1 (B). Complex formation reduces deuterium exchange within the nSH2 domain while simultaneously increasing deuterium exchange throughout the interface between the catalytic core and regulatory domains of PLC-γ1. Increased deuterium exchange is consistent with a loosening of the autoinhibited form of PLC-γ1 shown schematically. Active FGFR1 subsequently phosphorylates Tyr783 of PLC-γ1 to favor the interaction of pTyr783 and the cSH2 domain of PLC-γ1 (C). This step reinforces the disruption of the interface between regulatory and catalytic domains to favor a fully open form of PLC-γ1 capable of productively engaging membranes and manifesting as a decrease in the deuterium exchange of the catalytic TIM barrel (D).

What is much less well understood is the sequence of events culminating in the conformational rearrangements required for the activation of the PLC-γ isozymes. It is universally accepted that the phosphorylation of Tyr783 in PLC-γ1 or the equivalent residue, Tyr759, in PLC-γ2 is absolutely required for regulated activation, but the steps preceding or subsequent to these phosphorylations continue to be debated. The studies presented here address these less well-understood steps and support the view of the PLC-γ isozymes as relatively quiescent lipases prior to recruitment to membranes. Indeed, a major conclusion of these studies is that recruitment to membranes appears to be integral to activation.

Two aspects of this recruitment and activation deserve special consideration. First is the engagement of PLC-γ isozymes with RTKs or co-receptors. Complex formation requires receptors or co-receptors to be pre-phosphorylated at specific tyrosines to provide docking sites for the PLC-γ isozymes. Based on the majority of previous studies that address this point, the nSH2 domain of the PLC-γ isozymes directly engages phosphorylated tyrosines in the myriad of relevant, membrane-resident receptors and co-receptors. This point is also consistent with the relatively large decreases in amide proton exchange of the nSH2 domain of PLC-γ1 upon addition of the phosphorylated kinase domain of FGFR1. However, much more interesting is the widespread increases in amide exchange of PLC-γ1 upon complex formation. These widespread increases highlight a phospholipase that is exquisitely—and indeed, globally—tuned to engagement of the kinase. The most significant implication being that engagement of the nSH2 domain by a phosphorylated receptor or co-receptor increases the dynamic flexibility of large portions of the phospholipase. This increased flexibility will tend to loosen the autoinhibited state of the phospholipase to promote activation. In essence, initial recruitment of the PLC-γ isozymes to phosphorylated receptors or co-receptors is a crucial first step for lipase activation. We previously inferred this ‘priming’ step based solely on structural considerations, and the exchange data presented here strongly support this idea. Indeed, since priming is predicted to disfavor the autoinhibited state, it is also predicted to favor activation. Thus a priming step—that is independent of subsequent phosphorylation of PLC-γ1—readily explains the increased lipase activity of PLC-γ1 operating on membrane-embedded PIP2 and bound to the phosphorylated, but catalytically inactive, kinase domain of FGFR1.

The second aspect to consider is the intrinsic role of membranes during the activation of PLC-γ isozymes. Lipid vesicles containing PIP2 were relatively ineffectual in altering the amide exchange of WT PLC-γ1. This situation comports with the tight basal autoinhibition of PLC-γ isozymes in cells where the isozymes are inevitably in close proximity to lipid membranes. In contrast, the exchange kinetics of WT PLC-γ1 bound to the phosphorylated kinase domain of FGFR1 were amplified by the addition of lipid vesicles. Amplified exchange was even more extreme for PLC-γ1 (D1165H) containing a substitution introduced to perturb the interface between the catalytic core and regulatory domains (Hajicek et al., 2019). These results indicate that once primed by kinase—or indeed, mutation—PLC-γ1 becomes more sensitive to the presence of lipid vesicles. The net outcome likely shifts PLC-γ1 toward conformations that can productively engage membranes to hydrolyze membrane-bound PIP2.

These two aspects should not be considered in isolation. That is, the activation of PLC-γ isozymes involves the intertwined events of: (i) docking to membrane-resident receptors or co-receptors and (ii) the forced proximity at membranes of the dock complexes. The two events cooperate to initiate activation of PLC-γ isozymes (Figure 6), presumably by increasing accessibility to membrane-bound PIP2. At this point, it should be emphasized that the experimental setup studied here does not fully recapitulate the cellular activation process and almost certainly underestimates potential cooperativity. More specifically, to facilitate experimental tractability, and especially the desire to study complex formation independent of recruitment to membranes, these studies exclusively used an isolated kinase domain of FGFR1 not embedded in membranes. We predict cooperativity will be greatly enhanced for receptors or co-receptors embedded in membranes as typically found in cells. Increased cooperativity will result in increased sensitivity of activation of the PLC-γ isozymes. It should also be noted that these two steps along the activation pathway are general in that they are likely to manifest for any receptor or co-receptor that recruits PLC-γ1 or PLC-γ2 to membranes through motifs that contain phosphorylated tyrosine and bind the nSH2 domain of PLC-γ isozymes.

Up to this point, we have considered only membrane recruitment and activation of PLC-γ isozymes by phosphorylated receptors and co-receptors. However, these are not the only proteins that bind PLC-γ isozymes at membranes. For example, several scaffolding proteins such as SLP-76 that contain polyproline regions bind the SH3 domain of PLC-γ isozymes (Kim et al., 2000; Manna et al., 2018; Rouquette-Jazdanian et al., 2012; Tvorogov and Carpenter, 2002). Similarly, the small GTPase, Rac2, specifically engages the sPH domain of PLC-γ2 to promote lipase activation (Bunney et al., 2009; Piechulek et al., 2005; Walliser et al., 2008). We do not know if these complexes affect the conformational dynamics of the PLC-γ isozymes. However, if they do, these complexes may also prime the PLC-γ isozymes for activation at membranes with one potential outcome being an intricate interplay of multiple binding events regulating the activation of the PLC-γ isozymes.

Materials and methods

Key resources table
Reagent type(species) or resourceDesignationSource or referenceIdentifiersAdditional information
Strain, strain background (Escherichia coli)NEB 5-alphaNew England BioLabsCat# C2987IChemically competent cells
Strain, strain background (E. coli)DH10BacThermo Fisher ScientificCat# 10361012Chemically competent cells
Cell line (Trichoplusia ni)HighFiveInvitrogenCat# B85502
RRID:CVCL_C190
Recombinant DNA reagentpFB-LIC2-PLC-γ1 (21–1215) (plasmid)PMID:31889510Vector is a modified version of pFastBacHT1 containing His6 tag and TEV cleavage sequence
Recombinant DNA reagentpFB-LIC2-PLC-γ1(21–1215) H335A (plasmid)This paper Vector is a modified version of pFastBacHT1 containing His6 tag and TEV cleavage sequence
Recombinant DNA reagentpFB-LIC2-PLC-γ1(21–1215) H335A, D1165H (plasmid)This paper Vector is a modified version of pFastBacHT1 containing His6 tag and TEV cleavage sequence
Recombinant DNA reagentpUC57-Amp-FGFR1K(458-774) Y463F, Y583F, Y585F, Y730F (plasmid)This paper Cloning vector synthesized by Genewiz
Recombinant DNA reagentpFB-LIC2-FGFR1K(458-774) Y463F, Y583F, Y585F, Y730F (plasmid)This paper Vector is a modified version of pFastBacHT1 containing His6 tag and TEV cleavage sequence
Recombinant DNA reagentpFB-LIC2-FGFR1K(458-774) Y463F, Y583F, Y585F, Y730F, Y653F, Y654F (plasmid)This paper Vector is a modified version of pFastBacHT1 containing His6 tag and TEV cleavage sequence
Recombinant DNA reagentpFB-LIC2-FGFR1K(458-774) Y463F, Y583F, Y585F, Y730F, Y766F (plasmid)This paper Vector is a modified version of pFastBacHT1 containing His6 tag and TEV cleavage sequence
Chemical compound, drugL-α-phosphatidylethanolamine (Liver, Bovine)Avanti Polar LipidsCat# 840,026 
Chemical compound, drugL-α-phosphatidylinositol-4,5-bisphosphate (Brain, Porcine) (ammonium salt)Avanti Polar LipidsCat# 840,046 
Software, algorithmPEAKSBioinformatics Solutions Inc (BSI) Version 7 (PEAKS7)
Software, algorithmHDExaminerSierra Analytics  
Software, algorithmPyMOLPyMOL by SchrödingerRRID:SCR_000305Version 2.5.2
OtherWH-15PMID:21158426Fluorescent PIP2 analogue, soluble
OtherXY-69PMID:29263090Fluorescent PIP2 analogue, membrane-associated

Molecular cloning

Phospholipase C-γ1

Request a detailed protocol

Transfer vector (pFB-LIC2) encoding WT rat PLC-γ1 (residues 21–1215) and PLC-γ1 (D1165H) have been previously described (Hajicek et al., 2019). The H335A mutation that renders PLC-γ1 catalytically inactive was introduced into the transfer vector encoding WT PLC-γ1 (residues 21–1215) or PLC-γ1 (D1165H) using standard primer-mediated mutagenesis (Agilent Technologies; QuikChange site-directed mutagenesis manual). Mutagenesis was confirmed by automated DNA sequencing of the open reading frame. The PLCs encoded by these constructs are referred as PLC-γ1 (H335A) and PLC-γ1 (H335A+D1165H), respectively.

Kinase domain of the fibroblast growth factor receptor

Request a detailed protocol

Plasmid DNA encoding the kinase domain (residues 458–774) of human fibroblast growth factor receptor 1 (FGFR1) with four substitutions (Y463F, Y583F, Y585F, Y730F) that eliminate sites of phosphorylation was synthesized by Genewiz (South Plainfield, NJ). The plasmid DNA encoding this variant of FGFR1K was then sub-cloned from a pUC57-Amp vector to a modified pFastBac-HT vector (pFB-LIC2) using a ligation-independent cloning strategy. The baculovirus expression vector, pFB-LIC2, incorporates a His6 tag and a tobacco etch virus (TEV) protease site at the amino terminus of the expressed protein. This transfer vector was then mutated to encode two forms of FGFR1K: (i) a version mutated (Y653F and Y654F) to prevent phosphorylation-dependent activation of kinase activity, i.e., kinase inactive, and (ii) a version that retained kinase activity but was mutated (Y766F) to prevent phosphorylation-dependent interaction with PLC-γ1. Mutations were introduced using standard primer-mediated mutagenesis (Agilent Technologies; QuikChange site-directed mutagenesis manual) and all FGFR1K variants were verified by automated DNA sequencing of the corresponding open reading frames.

Protein expression and purification

Phospholipase C-γ1

Request a detailed protocol

Expression and purification of PLC-γ1 variants were previously described (Hajicek et al., 2019) and used here with minor modifications. Briefly, 4 L of High Five (Trichoplusia ni) cells at a density of approximately 2.0 × 106 cells/mL were infected with amplified baculovirus stock (10–15 mL/L) encoding individual PLC-γ1 variants. Cells were harvested approximately 48 hr post-infection by centrifugation at 6,000 rpm in a Beckman JA-10 rotor at 4°C. Cell pellet was resuspended in 200 mL of buffer N1 (20 mM HEPES [pH 7.5], 300 mM NaCl, 10 mM imidazole, 10% v/v glycerol, and 0.1 mM EDTA) supplemented with 10 mM 2-mercaptoethanol and four EDTA-free cOmplete protease inhibitor tablets (Roche Applied Science) prior to lysis using the Nano DeBEE High Pressure Homogenizer (BEE International). Lysate was centrifuged at 50,000 rpm for 1 hr in a Beckman Ti70 rotor. The supernatant was filtered through a 0.45 μm polyethersulfone low protein-binding filter and loaded onto a 5 mL HisTrap HP immobilized metal affinity chromatography (IMAC) column equilibrated in buffer N1. The column was washed with 15 column volumes (CV) of buffer N1, followed by 15 CV of 2.5% buffer N2 (buffer N1 + 1 M imidazole). Bound proteins were eluted with 40% buffer N2. Fractions containing PLC-γ1 were pooled and dialyzed overnight in the presence of 2% (w/w) TEV protease to remove the His6 tag in a buffer solution containing 20 mM HEPES (pH 7.5), 300 mM NaCl, 10% v/v glycerol, 1 mM dithiothreitol (DTT), 1 mM EDTA. The sample was subsequently diluted two-fold with buffer N1 and applied to a 5 mL HisTrap HP column. Flow-through fractions containing cleaved PLC-γ1 were pooled, diluted four-fold with buffer Q1 (20 mM HEPES (pH 7.5) and 2 mM DTT), and loaded onto an 8 mL SourceQ anion exchange column equilibrated in 10% buffer Q2 (buffer Q1 +1 M NaCl). Bound proteins were eluted in a linear gradient of 10–60% buffer Q2 over 50 CV. Fractions containing PLC-γ1 were pooled, concentrated using a GE Healthcare VivaSpin 6 50K molecular weight cut-off (MWCO) centrifugal concentrator and applied to a 16 mm × 700 mm HiLoad Superdex 200 size exclusion column equilibrated in a buffer solution containing 20 mM HEPES (pH 7.5), 150 mM NaCl, 5% v/v glycerol, and 2 mM DTT. Pure PLC-γ1 was concentrated to a final concentration of 40–80 mg/mL, aliquoted, snap-frozen in liquid nitrogen, and stored at –80°C until use.

Kinase domain of the fibroblast growth factor receptor

Request a detailed protocol

Expression and purification of kinase-inactive FGFR1K follows that of the PLC-γ1 variants with the following modifications. After removal of the His6 tag by TEV protease and subsequent 5 mL HisTrap HP IMAC column, the sample was concentrated using a GE Healthcare VivaSpin 6 10K MWCO centrifugal concentrator. Concentrated sample was applied to a 16 mm × 700 mm HiLoad Superdex 200 size exclusion column equilibrated in buffer containing 20 mM HEPES (pH 7.5), 200 mM NaCl, 5% (v/v) glycerol, and 2 mM DTT. Fractions containing pure, kinase-inactive FGFR1K were concentrated to a final concentration of 20–30 mg/mL, aliquoted, snap-frozen in liquid nitrogen, and stored at –80°C until use. The kinase active form of FGFR1K harboring Y766F was expressed as described above; however, purification terminated after the first 5 mL HisTrap HP IMAC column so the protein retains its His6 tag.

In vitro phosphorylation of FGFR1K

Request a detailed protocol

Equimolar concentrations (100 μM) of tagless, kinase-inactive FGFR1K and the tagged, kinase-active version were incubated in 20 mM HEPES (pH 7.5), 50 mM NaCl, 25 mM MgCl2, 50 ng/mL fatty acid-free bovine serum albumin (FAF BSA), 10 mM ATP, and 2 mM DTT. The phosphorylation reaction was terminated after 100 min by adding EDTA to a final concentration of 50 mM and kinase phosphorylation was confirmed via native PAGE followed by staining with Coomassie Brilliant Blue. To separate the two forms of FGFR1K, the mixture was loaded onto a 1 mL HisTrap HP IMAC using a 200 μL sample loop followed by 2 mL of buffer N1 (20 mM HEPES pH 7.5, 100 mM NaCl, 10 mM MgCl2, and 2 mM DTT). The column was washed with 5 CV of buffer N1, followed by 5 CV of 40% buffer N2 (buffer N1 + 1 M imidazole), and 5 CV of 100% buffer N2. Fractions containing phosphorylated, kinase-inactive FGFR1K were pooled and concentrated using a GE Healthcare Vivaspin 6 10K MWCO, aliquoted, snap-frozen in liquid nitrogen, and stored at –80°C until use.

LC-MS/MS of phosphorylated FGFR1K

Request a detailed protocol

Phosphorylated, kinase-inactive FGFR1K was diluted and loaded onto native PAGE followed by staining with Coomassie Brilliant Blue. Gel bands were excised and digested with trypsin overnight. Peptides were extracted, then analyzed by LC-MS/MS using the Thermo Easy nLC 1200-QExactive HF. Data were searched against a UniProt Sf9 database including the sequence for FGFR1K using Sequest within Proteome Discoverer 2.1. All data were filtered using a false discovery rate of 5%.

Formation of PLC-γ1 in complex with FGFR1K

Request a detailed protocol

Kinase-inactive FGFR1K phosphorylated at Tyr766 was generated as described above. Either PLC-γ1 (H335A) or PLC-γ1 (H335A+D1165H) was added in a two-fold molar excess relative to kinase. The sample was immediately loaded onto a 10 mm × 300 mm Superdex 200 GL size exclusion column equilibrated with 20 mM HEPES (pH 7.5), 100 mM NaCl, 10 mM MgCl2, and 2 mM DTT. Pure complex was pooled and concentrated using a GE Healthcare Vivaspin 6 10K MWCO, aliquoted, snap-frozen in liquid nitrogen, and stored at –80°C until use. Formation of the complex was confirmed via SDS-PAGE followed by staining with Coomassie Brilliant Blue.

In vitro quantification of phospholipase activity

XY-69 fluorogenic assay

Request a detailed protocol

Liposomes with a final PE:PIP2 content of 80:20 were generated by mixing 750 nM XY-69 (Huang et al., 2018), 192 μM of liver phosphatidylethanolamine (PE, Avanti Polar Lipids), 48 μM brain PIP2 (Avanti Polar Lipids) in 12 × 75 mm borosilicate tubes. Lipids were dried under a nitrogen stream followed by high vacuum (0.5 mtorr). Dried lipid mixture was suspended in 20 mM HEPES (pH 7.5) using a probe microtip sonicator of 5/64" at 20% output for three cycles of 5 s ON, 15 s OFF. Concurrently, the PLC-γ1 proteins were diluted in a buffer containing 20 mM HEPES (pH 7.5), 50 mM NaCl, 2 mM DTT, and 1 mg/mL FAF BSA. The 6X assay buffer containing 80 mM HEPES (pH 7.5), 420 mM KCl, 10 mM DTT, 18 mM EGTA, and 14.1 mM CaCl2 (~390 nM free Ca2+) was added to the resuspended lipid mixture in a 1:4 ratio. To a non-binding surface-treated Corning 384-well plate, 2 μL of diluted PLC-γ1 proteins were added, either alone or in the presence of a two-fold molar excess of unphosphorylated or phosphorylated, kinase-inactive FGFR1K relative to PLC-γ1. To initiate the assay, 10 μL of the lipid and assay buffer mixture were added. The plates were incubated at 30°C and data was recorded for 30 min at intervals of 1 min using excitation and emission wavelengths of 485 nm and 520 nm, respectively. Fluorescence intensity was normalized to a blank reaction lacking phospholipase, and initial rates of XY-69 hydrolysis were calculated from the slope of the linear portion of the curve. Final concentrations of XY-69, PIP2, and PE were 5 μM, 48 μM, and 192 μM, respectively.

WH-15 fluorogenic assay

Request a detailed protocol

Assays with the soluble substrate WH-15 were performed as described previously (Huang et al., 2011) with the following modifications. WH-15 was diluted to a final concentration of 5 μM in assay buffer containing 50 mM HEPES (pH 7.5), 70 mM KCl, 3 mM EGTA, 2.97 mM CaCl2 (~10 μM free Ca2+), 50 μg/mL FAF BSA, and 2 mM DTT. Basal fluorescence was equilibrated for approximately 10 min before addition of PLC-γ1 (D1165H) alone or in the presence of a two-fold molar excess of unphosphorylated or phosphorylated, kinase-inactive FGFR1K relative to PLC-γ1 (1 nM, final concentration). Data were recorded for 1 hr at intervals of 30 s using excitation and emission wavelengths of 488 nm and 520 nm, respectively. Fluorescence intensity was normalized to the reaction lacking phospholipase, and initial rates of WH-15 hydrolysis were calculated from the slope of the linear portion of the curve.

Liposome flotation assay

Request a detailed protocol

Liposomes with a final content of 89.8% PE, 10% PIP2, and 0.2% 7-nitro-2–1,3-benzoxadiazol-4-yl-PE were dried down and resuspended in 20 mM HEPES (pH 7.5) by sonication as described above for assays using XY-69. Concurrently PLC-γ1 (H335A), alone or in complex with phosphorylated, kinase-inactive FGFR1K was diluted in assay buffer containing 100 mM HEPES (pH 7.5), 150 mM NaCl, 10 mM KCl, 10 μM CaCl2, 0.5 mM tris(2-carboxyethyl)phosphine (TCEP). PLC-γ1 and liposomes were mixed and incubated on ice for 2 min. Immediately after mixing, 100 μL of assay buffer with 75% sucrose were added to the protein-lipid mixture to a final concentration of 30% sucrose in 250 μL total volume. The samples were overlaid with 200 μL of assay buffer with 25% sucrose and 50 μL of assay buffer. Samples were centrifuged at 55,000 rpm in a TLS-55 rotor for 1 hr at 4°C. After centrifugation, three fractions were collected: bottom (B, 250 μL), middle (M, 150 μL), and top (T, 100 μL). Samples (30 μL) of each fraction were mixed with 7 μL of 6X SDS sample buffer and analyzed by SDS-PAGE followed by staining with Coomassie Brilliant Blue.

Hydrogen-deuterium exchange mass spectrometry

Sample preparation

Request a detailed protocol

Exchange reactions were carried out at 18°C in 20 μL volumes with a final concentration of 1.25 μM PLC-γ1 (H335A), PLC-γ1 (H335A+D1165H), PLC-γ1 (H335A)-FGFR1K complex, or PLC-γ1 (H335A+D1165H)-FGFR1K complex. A total of eight conditions were assessed: four in the presence of liposomes containing 90% PE and 10% PIP2 and four in the absence of liposomes. PLC-γ1 biochemical assays have showed similar activity of vesicles of varying composition (e.g., PC/PS/PIP2/cholesterol), so the PE/PIP2 mixture was used for its experimental simplicity. The conditions were as follows:

  • PLC-γ1 (H335A) alone

  • PLC-γ1 (H335A+D1165H) alone

  • PLC-γ1 (H335A)−FGFR1K

  • PLC-γ1 (H335A+D1165H)−FGFR1K

  • PLC-γ1 (H335A)+liposomes

  • PLC-γ1 (H335A+D1165H)+liposomes

  • PLC-γ1 (H335A)−FGFR1K+liposomes

  • PLC-γ1 (H335A+D1165H)−FGFR1K+liposomes

For conditions containing liposomes, lipids were present at a final concentration of 320 µM. Prior to the addition of D2O, 2.0 μL of liposomes (or liposome buffer [20 mM HEPES pH 7.5, 100 mM KCl]) were added to 1.5 μL of protein, and the solution was left to incubate at 18°C for 2 min. Hydrogen-deuterium exchanges were initiated by the addition of 16.5 μL D2O buffer (88% D2O, 150 mM NaCl, 100 mM HEPES pH 7.0, 10 µM CaCl2, 0.5 mM TCEP pH 7.5)–3.5 μL protein or protein-liposome solution for a final D2O concentration of 72%. Exchange was carried out over five time points (3, 30, 300, 3000, and 10,000 s) and terminated by the addition of 50 μL ice-cold acidic quench buffer (0.8 M guanidine-HCl, 1.2% formic acid). After quenching, samples were immediately frozen in liquid nitrogen and stored at –80°C. All reactions were carried out in triplicate.

For PLC-γ1 (H335A) versus PLC-γ1 (H335A+D1165H), exchange reactions were carried out at 18°C in 50 μL volumes with a final concentration of 0.4 μM PLC-γ1 or PLC-γ1 (D1165H). Hydrogen-deuterium exchanges were initiated by the addition of 49 μL D2O buffer (89% D2O, 100 mM NaCl, 50 mM HEPES pH 7.5)–1 μL protein for a final D2O concentration of 87%. Exchange was carried out over five time points (3 s on ice and 3, 30, 300, 3000 s at RT) and terminated by the addition of 20 μL ice-cold acidic quench buffer (2 M guanidine-HCl, 3% formic acid). After quenching, samples were immediately frozen in liquid nitrogen and stored at –80°C. All reactions were carried out in triplicate.

Protein digestion and MS/MS data collection

Request a detailed protocol

Protein samples were rapidly thawed and injected onto an integrated fluidics system containing a HDX-3 PAL liquid handling robot and climate-controlled chromatography system (LEAP Technologies), a Dionex Ultimate 3000 UHPLC system, as well as an Impact HD QTOF Mass spectrometer (Bruker). Proteins were run over two immobilized pepsin columns (Applied Biosystems; Poroszyme Immobilized Pepsin Cartridge, 2.1 mm × 30 mm; Thermo-Fisher 2‐3131‐00; at 10 and 2°C, respectively) at 200 μL/min for 3 min. The resulting peptides were collected and desalted on a C18 trap column (Acquity UPLC BEH C18 1.7 µm column [2.1 × 5 mm]; Waters 186002350). The trap was subsequently eluted in line with a C18 reverse-phase separation column (Acquity 1.7 μm particle, 100 × 1 mm2 C18 UPLC column, Waters 186002352), using a gradient of 5–36% B (buffer A 0.1% formic acid; buffer B 100% acetonitrile) over 16 min. Lipids were directly captured on the LC system, and eluted off at the 100% acetonitrile step, with no interference on mass spectrometer or LC performance. Full details of the LC setup and gradient for lipid samples are in Stariha et al., 2021. Mass spectrometry experiments were performed on an Impact II QTOF (Bruker) acquiring over a mass range from 150 to 2200 m/z using an electrospray ionization source operated at a temperature of 200°C and a spray voltage of 4.5 kV.

Peptide identification

Request a detailed protocol

Peptides were identified using data-dependent acquisition following tandem MS/MS experiments (0.5 s precursor scan from 150 to 2000 m/z; twelve 0.25 s fragment scans from 150 to 2000 m/z). MS/MS datasets were analyzed using PEAKS7 (PEAKS), and a false discovery rate was set at 1% using a database of purified proteins and known contaminants (Dobbs et al., 2020).

Mass analysis of peptide centroids and measurement of deuterium incorporation

Request a detailed protocol

HD‐Examiner Software (Sierra Analytics) was used to automatically calculate the level of deuterium incorporation into each peptide. All peptides were manually inspected for correct charge state, correct retention time, absence of overlapping isotopic traces, and appropriate selection of isotopic distribution. Deuteration levels were calculated using the centroid of the experimental isotope clusters. Results for these proteins are presented as relative levels of deuterium incorporation and the only control for back exchange was the level of deuterium present in the buffer (72%). Changes in any peptide at any time point (3, 30, 300, 3000, and 10,000 s) greater than specified cut-offs (5% and 0.4 Da) and with an unpaired, two-tailed t-test value of p<0.01 were considered significant.

The raw peptide deuterium incorporation graphs for a selection of peptides with significant differences are shown (Figure 3, Figure 2—figure supplement 4, Figure 4—figure supplement 1), with the raw data for all analyzed peptides in the source Excel file. To allow for visualization of differences across all peptides, we used number of deuteron difference (#D) plots (Figures 2—4, Figure 2—figure supplement 4, Figure 4—figure supplement 1, Figure 4—figure supplement 2). These plots show the total difference in deuterium incorporation over the entire HDX time course, with each point indicating a single peptide. These graphs are calculated by summing the differences at every time point for each peptide and propagating the error (e.g. Figure 2A). For a selection of peptides, we are showing the %D incorporation over a time course, which allows for comparison of multiple conditions at the same time for a given region (Figure 2—figure supplement 4, Figure 4—figure supplement 1). Samples were only compared within a single experiment and were never compared to experiments completed at a different time with a different final D2O level. The data analysis statistics for all HDX-MS experiments are in Supplementary file 1 and conform to recommended guidelines (Masson et al., 2019). The MS proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository (Perez-Riverol et al., 2019) with the dataset identifier PXD030492.

Data availability

All HDX-MS data have been deposited to the ProteomeXchange Consortium with dataset identifier PXC030492.

The following data sets were generated

References

    1. Kim JW
    2. Sim SS
    3. Kim UH
    4. Nishibe S
    5. Wahl MI
    6. Carpenter G
    7. Rhee SG
    (1990)
    Tyrosine residues in bovine phospholipase C-gamma phosphorylated by the epidermal growth factor receptor in vitro
    The Journal of Biological Chemistry 265:3940–3943.
    1. Sims R
    2. van der Lee SJ
    3. Naj AC
    4. Bellenguez C
    5. Badarinarayan N
    6. Jakobsdottir J
    7. Kunkle BW
    8. Boland A
    9. Raybould R
    10. Bis JC
    11. Martin ER
    12. Grenier-Boley B
    13. Heilmann-Heimbach S
    14. Chouraki V
    15. Kuzma AB
    16. Sleegers K
    17. Vronskaya M
    18. Ruiz A
    19. Graham RR
    20. Olaso R
    21. Hoffmann P
    22. Grove ML
    23. Vardarajan BN
    24. Hiltunen M
    25. Nöthen MM
    26. White CC
    27. Hamilton-Nelson KL
    28. Epelbaum J
    29. Maier W
    30. Choi S-H
    31. Beecham GW
    32. Dulary C
    33. Herms S
    34. Smith AV
    35. Funk CC
    36. Derbois C
    37. Forstner AJ
    38. Ahmad S
    39. Li H
    40. Bacq D
    41. Harold D
    42. Satizabal CL
    43. Valladares O
    44. Squassina A
    45. Thomas R
    46. Brody JA
    47. Qu L
    48. Sánchez-Juan P
    49. Morgan T
    50. Wolters FJ
    51. Zhao Y
    52. Garcia FS
    53. Denning N
    54. Fornage M
    55. Malamon J
    56. Naranjo MCD
    57. Majounie E
    58. Mosley TH
    59. Dombroski B
    60. Wallon D
    61. Lupton MK
    62. Dupuis J
    63. Whitehead P
    64. Fratiglioni L
    65. Medway C
    66. Jian X
    67. Mukherjee S
    68. Keller L
    69. Brown K
    70. Lin H
    71. Cantwell LB
    72. Panza F
    73. McGuinness B
    74. Moreno-Grau S
    75. Burgess JD
    76. Solfrizzi V
    77. Proitsi P
    78. Adams HH
    79. Allen M
    80. Seripa D
    81. Pastor P
    82. Cupples LA
    83. Price ND
    84. Hannequin D
    85. Frank-García A
    86. Levy D
    87. Chakrabarty P
    88. Caffarra P
    89. Giegling I
    90. Beiser AS
    91. Giedraitis V
    92. Hampel H
    93. Garcia ME
    94. Wang X
    95. Lannfelt L
    96. Mecocci P
    97. Eiriksdottir G
    98. Crane PK
    99. Pasquier F
    100. Boccardi V
    101. Henández I
    102. Barber RC
    103. Scherer M
    104. Tarraga L
    105. Adams PM
    106. Leber M
    107. Chen Y
    108. Albert MS
    109. Riedel-Heller S
    110. Emilsson V
    111. Beekly D
    112. Braae A
    113. Schmidt R
    114. Blacker D
    115. Masullo C
    116. Schmidt H
    117. Doody RS
    118. Spalletta G
    119. Longstreth WT Jr
    120. Fairchild TJ
    121. Bossù P
    122. Lopez OL
    123. Frosch MP
    124. Sacchinelli E
    125. Ghetti B
    126. Yang Q
    127. Huebinger RM
    128. Jessen F
    129. Li S
    130. Kamboh MI
    131. Morris J
    132. Sotolongo-Grau O
    133. Katz MJ
    134. Corcoran C
    135. Dunstan M
    136. Braddel A
    137. Thomas C
    138. Meggy A
    139. Marshall R
    140. Gerrish A
    141. Chapman J
    142. Aguilar M
    143. Taylor S
    144. Hill M
    145. Fairén MD
    146. Hodges A
    147. Vellas B
    148. Soininen H
    149. Kloszewska I
    150. Daniilidou M
    151. Uphill J
    152. Patel Y
    153. Hughes JT
    154. Lord J
    155. Turton J
    156. Hartmann AM
    157. Cecchetti R
    158. Fenoglio C
    159. Serpente M
    160. Arcaro M
    161. Caltagirone C
    162. Orfei MD
    163. Ciaramella A
    164. Pichler S
    165. Mayhaus M
    166. Gu W
    167. Lleó A
    168. Fortea J
    169. Blesa R
    170. Barber IS
    171. Brookes K
    172. Cupidi C
    173. Maletta RG
    174. Carrell D
    175. Sorbi S
    176. Moebus S
    177. Urbano M
    178. Pilotto A
    179. Kornhuber J
    180. Bosco P
    181. Todd S
    182. Craig D
    183. Johnston J
    184. Gill M
    185. Lawlor B
    186. Lynch A
    187. Fox NC
    188. Hardy J
    189. ARUK Consortium
    190. Albin RL
    191. Apostolova LG
    192. Arnold SE
    193. Asthana S
    194. Atwood CS
    195. Baldwin CT
    196. Barnes LL
    197. Barral S
    198. Beach TG
    199. Becker JT
    200. Bigio EH
    201. Bird TD
    202. Boeve BF
    203. Bowen JD
    204. Boxer A
    205. Burke JR
    206. Burns JM
    207. Buxbaum JD
    208. Cairns NJ
    209. Cao C
    210. Carlson CS
    211. Carlsson CM
    212. Carney RM
    213. Carrasquillo MM
    214. Carroll SL
    215. Diaz CC
    216. Chui HC
    217. Clark DG
    218. Cribbs DH
    219. Crocco EA
    220. DeCarli C
    221. Dick M
    222. Duara R
    223. Evans DA
    224. Faber KM
    225. Fallon KB
    226. Fardo DW
    227. Farlow MR
    228. Ferris S
    229. Foroud TM
    230. Galasko DR
    231. Gearing M
    232. Geschwind DH
    233. Gilbert JR
    234. Graff-Radford NR
    235. Green RC
    236. Growdon JH
    237. Hamilton RL
    238. Harrell LE
    239. Honig LS
    240. Huentelman MJ
    241. Hulette CM
    242. Hyman BT
    243. Jarvik GP
    244. Abner E
    245. Jin L-W
    246. Jun G
    247. Karydas A
    248. Kaye JA
    249. Kim R
    250. Kowall NW
    251. Kramer JH
    252. LaFerla FM
    253. Lah JJ
    254. Leverenz JB
    255. Levey AI
    256. Li G
    257. Lieberman AP
    258. Lunetta KL
    259. Lyketsos CG
    260. Marson DC
    261. Martiniuk F
    262. Mash DC
    263. Masliah E
    264. McCormick WC
    265. McCurry SM
    266. McDavid AN
    267. McKee AC
    268. Mesulam M
    269. Miller BL
    270. Miller CA
    271. Miller JW
    272. Morris JC
    273. Murrell JR
    274. Myers AJ
    275. O’Bryant S
    276. Olichney JM
    277. Pankratz VS
    278. Parisi JE
    279. Paulson HL
    280. Perry W
    281. Peskind E
    282. Pierce A
    283. Poon WW
    284. Potter H
    285. Quinn JF
    286. Raj A
    287. Raskind M
    288. Reisberg B
    289. Reitz C
    290. Ringman JM
    291. Roberson ED
    292. Rogaeva E
    293. Rosen HJ
    294. Rosenberg RN
    295. Sager MA
    296. Saykin AJ
    297. Schneider JA
    298. Schneider LS
    299. Seeley WW
    300. Smith AG
    301. Sonnen JA
    302. Spina S
    303. Stern RA
    304. Swerdlow RH
    305. Tanzi RE
    306. Thornton-Wells TA
    307. Trojanowski JQ
    308. Troncoso JC
    309. Van Deerlin VM
    310. Van Eldik LJ
    311. Vinters HV
    312. Vonsattel JP
    313. Weintraub S
    314. Welsh-Bohmer KA
    315. Wilhelmsen KC
    316. Williamson J
    317. Wingo TS
    318. Woltjer RL
    319. Wright CB
    320. Yu C-E
    321. Yu L
    322. Garzia F
    323. Golamaully F
    324. Septier G
    325. Engelborghs S
    326. Vandenberghe R
    327. De Deyn PP
    328. Fernadez CM
    329. Benito YA
    330. Thonberg H
    331. Forsell C
    332. Lilius L
    333. Kinhult-Stählbom A
    334. Kilander L
    335. Brundin R
    336. Concari L
    337. Helisalmi S
    338. Koivisto AM
    339. Haapasalo A
    340. Dermecourt V
    341. Fievet N
    342. Hanon O
    343. Dufouil C
    344. Brice A
    345. Ritchie K
    346. Dubois B
    347. Himali JJ
    348. Keene CD
    349. Tschanz J
    350. Fitzpatrick AL
    351. Kukull WA
    352. Norton M
    353. Aspelund T
    354. Larson EB
    355. Munger R
    356. Rotter JI
    357. Lipton RB
    358. Bullido MJ
    359. Hofman A
    360. Montine TJ
    361. Coto E
    362. Boerwinkle E
    363. Petersen RC
    364. Alvarez V
    365. Rivadeneira F
    366. Reiman EM
    367. Gallo M
    368. O’Donnell CJ
    369. Reisch JS
    370. Bruni AC
    371. Royall DR
    372. Dichgans M
    373. Sano M
    374. Galimberti D
    375. St George-Hyslop P
    376. Scarpini E
    377. Tsuang DW
    378. Mancuso M
    379. Bonuccelli U
    380. Winslow AR
    381. Daniele A
    382. Wu C-K
    383. GERAD/PERADES, CHARGE, ADGC, EADI
    384. Peters O
    385. Nacmias B
    386. Riemenschneider M
    387. Heun R
    388. Brayne C
    389. Rubinsztein DC
    390. Bras J
    391. Guerreiro R
    392. Al-Chalabi A
    393. Shaw CE
    394. Collinge J
    395. Mann D
    396. Tsolaki M
    397. Clarimón J
    398. Sussams R
    399. Lovestone S
    400. O’Donovan MC
    401. Owen MJ
    402. Behrens TW
    403. Mead S
    404. Goate AM
    405. Uitterlinden AG
    406. Holmes C
    407. Cruchaga C
    408. Ingelsson M
    409. Bennett DA
    410. Powell J
    411. Golde TE
    412. Graff C
    413. De Jager PL
    414. Morgan K
    415. Ertekin-Taner N
    416. Combarros O
    417. Psaty BM
    418. Passmore P
    419. Younkin SG
    420. Berr C
    421. Gudnason V
    422. Rujescu D
    423. Dickson DW
    424. Dartigues J-F
    425. DeStefano AL
    426. Ortega-Cubero S
    427. Hakonarson H
    428. Campion D
    429. Boada M
    430. Kauwe JK
    431. Farrer LA
    432. Van Broeckhoven C
    433. Ikram MA
    434. Jones L
    435. Haines JL
    436. Tzourio C
    437. Launer LJ
    438. Escott-Price V
    439. Mayeux R
    440. Deleuze J-F
    441. Amin N
    442. Holmans PA
    443. Pericak-Vance MA
    444. Amouyel P
    445. van Duijn CM
    446. Ramirez A
    447. Wang L-S
    448. Lambert J-C
    449. Seshadri S
    450. Williams J
    451. Schellenberg GD
    (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease
    Nature Genetics 49:1373–1384.
    https://doi.org/10.1038/ng.3916

Article and author information

Author details

  1. Edhriz Siraliev-Perez

    Department of Biochemistry and Biophysics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States
    Contribution
    Conceptualization, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1824-863X

  2. Jordan TB Stariha

    Department of Biochemistry and Microbiology, University of Victoria, Victoria, Canada
    Contribution
    Investigation, Methodology
    Competing interests
    No competing interests declared

  3. Reece M Hoffmann

    Department of Biochemistry and Microbiology, University of Victoria, Victoria, Canada
    Contribution
    Investigation, Methodology
    Competing interests
    No competing interests declared

  4. Brenda RS Temple

    Department of Biochemistry and Biophysics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States
    Contribution
    Methodology
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9233-0191

  5. Qisheng Zhang

    1. Department of Biochemistry and Biophysics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States
    2. Division of Chemical Biology and Medicinal Chemistry, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States
    3. Lineberger Comprehensive Cancer Center, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States
    Contribution
    Methodology, Resources
    Competing interests
    No competing interests declared

  6. Nicole Hajicek

    Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States
    Contribution
    Conceptualization, Formal analysis, Project administration, Supervision, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7457-4830

  7. Meredith L Jenkins

    Department of Biochemistry and Microbiology, University of Victoria, Victoria, Canada
    Contribution
    Investigation, Methodology
    Competing interests
    No competing interests declared

  8. John E Burke

    1. Department of Biochemistry and Microbiology, University of Victoria, Victoria, Canada
    2. Department of Biochemistry and Molecular Biology, The University of British Columbia, Vancouver, Canada
    Contribution
    Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Software, Supervision, Validation, Visualization, Writing – review and editing
    For correspondence
    jeburke@uvic.ca
    Competing interests
    Burke reports consulting fees from Scorpion Therapeutics and Olema Oncology, and research grants from Novartis, which are all outside the scope of this work
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7904-9859

  9. John Sondek

    1. Department of Biochemistry and Biophysics, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States
    2. Lineberger Comprehensive Cancer Center, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, United States
    3. Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, United States
    Contribution
    Conceptualization, Formal analysis, Funding acquisition, Project administration, Supervision, Writing – original draft, Writing – review and editing
    For correspondence
    sondek@med.unc.edu
    Competing interests
    Partial ownership of KXTbio, Inc which licenses the production of WH-15
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1127-8310

Funding

National Institutes of Health (R01-GM057391)

  • John Sondek

National Institutes of Health (R01-GM098894)

  • Qisheng Zhang
  • John Sondek

Government of Canada (Natural Science and Engineering Research Council of Canada NSERC-2020-04241)

  • John E Burke

Michael Smith Foundation for Health Research (Scholar Award 17686)

  • John E Burke

National Science Foundation (DGE-1650116)

  • Edhriz Siraliev-Perez

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

We acknowledge members of the Sondek and Burke labs for their valuable feedback and technical support. We also thank Laura Herring and Josh Beri at the UNC Michael Hooker Proteomics Center for assistance with LC-MS/MS of phosphorylated kinase. This work was supported by The National Institutes of Health Grants R01-GM057391 (JS) and R01-GM098894 (QZ and JS), the Natural Science and Engineering Research Council of Canada (JEB, Discovery grant NSERC-2020–04241) and the Michael Smith Foundation for Health Research (JEB, Scholar Award 17686). ES-P was supported by a National Science Foundation Graduate Research Fellowship under Grant No. DGE-1650116.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Copyright

© 2022, Siraliev-Perez et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,043
    views
  • 214
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Edhriz Siraliev-Perez
  2. Jordan TB Stariha
  3. Reece M Hoffmann
  4. Brenda RS Temple
  5. Qisheng Zhang
  6. Nicole Hajicek
  7. Meredith L Jenkins
  8. John E Burke
  9. John Sondek
(2022)
Dynamics of allosteric regulation of the phospholipase C-γ isozymes upon recruitment to membranes
eLife 11:e77809.
https://doi.org/10.7554/eLife.77809

Share this article

https://doi.org/10.7554/eLife.77809

Categories and tags

Further reading

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease

    Malaria parasites require a divergent heme oxygenase for apicoplast gene expression and biogenesis

    Amanda Mixon Blackwell, Yasaman Jami-Alahmadi ... Paul A Sigala
    Research Article

    Malaria parasites have evolved unusual metabolic adaptations that specialize them for growth within heme-rich human erythrocytes. During blood-stage infection, Plasmodium falciparum parasites internalize and digest abundant host hemoglobin within the digestive vacuole. This massive catabolic process generates copious free heme, most of which is biomineralized into inert hemozoin. Parasites also express a divergent heme oxygenase (HO)-like protein (PfHO) that lacks key active-site residues and has lost canonical HO activity. The cellular role of this unusual protein that underpins its retention by parasites has been unknown. To unravel PfHO function, we first determined a 2.8 Å-resolution X-ray structure that revealed a highly α-helical fold indicative of distant HO homology. Localization studies unveiled PfHO targeting to the apicoplast organelle, where it is imported and undergoes N-terminal processing but retains most of the electropositive transit peptide. We observed that conditional knockdown of PfHO was lethal to parasites, which died from defective apicoplast biogenesis and impaired isoprenoid-precursor synthesis. Complementation and molecular-interaction studies revealed an essential role for the electropositive N-terminus of PfHO, which selectively associates with the apicoplast genome and enzymes involved in nucleic acid metabolism and gene expression. PfHO knockdown resulted in a specific deficiency in levels of apicoplast-encoded RNA but not DNA. These studies reveal an essential function for PfHO in apicoplast maintenance and suggest that Plasmodium repurposed the conserved HO scaffold from its canonical heme-degrading function in the ancestral chloroplast to fulfill a critical adaptive role in organelle gene expression.

    1. Biochemistry and Chemical Biology
    2. Cell Biology

    Endogenous oligomer formation underlies DVL2 condensates and promotes Wnt/β-catenin signaling

    Senem Ntourmas, Martin Sachs ... Dominic B Bernkopf
    Research Article

    Activation of the Wnt/β-catenin pathway crucially depends on the polymerization of dishevelled 2 (DVL2) into biomolecular condensates. However, given the low affinity of known DVL2 self-interaction sites and its low cellular concentration, it is unclear how polymers can form. Here, we detect oligomeric DVL2 complexes at endogenous protein levels in human cell lines, using a biochemical ultracentrifugation assay. We identify a low-complexity region (LCR4) in the C-terminus whose deletion and fusion decreased and increased the complexes, respectively. Notably, LCR4-induced complexes correlated with the formation of microscopically visible multimeric condensates. Adjacent to LCR4, we mapped a conserved domain (CD2) promoting condensates only. Molecularly, LCR4 and CD2 mediated DVL2 self-interaction via aggregating residues and phenylalanine stickers, respectively. Point mutations inactivating these interaction sites impaired Wnt pathway activation by DVL2. Our study discovers DVL2 complexes with functional importance for Wnt/β-catenin signaling. Moreover, we provide evidence that DVL2 condensates form in two steps by pre-oligomerization via high-affinity interaction sites, such as LCR4, and subsequent condensation via low-affinity interaction sites, such as CD2.

    1. Biochemistry and Chemical Biology

    Identification of suitable target/E3 ligase pairs for PROTAC development using a rapamycin-induced proximity assay (RiPA)

    Bikash Adhikari, Katharina Schneider ... Elmar Wolf
    Research Article

    The development of proteolysis targeting chimeras (PROTACs), which induce the degradation of target proteins by bringing them into proximity with cellular E3 ubiquitin ligases, has revolutionized drug development. While the human genome encodes more than 600 different E3 ligases, current PROTACs use only a handful of them, drastically limiting their full potential. Furthermore, many PROTAC development campaigns fail because the selected E3 ligase candidates are unable to induce degradation of the particular target of interest. As more and more ligands for novel E3 ligases are discovered, the chemical effort to identify the best E3 ligase for a given target is exploding. Therefore, a genetic system to identify degradation-causing E3 ligases and suitable target/E3 ligase pairs is urgently needed. Here, we used the well-established dimerization of the FKBP12 protein and FRB domain by rapamycin to bring the target protein WDR5 into proximity with candidate E3 ligases. Strikingly, this rapamycin-induced proximity assay (RiPA) revealed that VHL, but not Cereblon, is able to induce WDR5 degradation - a finding previously made by PROTACs, demonstrating its predictive power. By optimizing the steric arrangement of all components and fusing the target protein with a minimal luciferase, RiPA can identify the ideal E3 for any target protein of interest in living cells, significantly reducing and focusing the chemical effort in the early stages of PROTAC development.